EE03473B1 - Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon - Google Patents

Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon

Info

Publication number
EE03473B1
EE03473B1 EE9700244A EE9700244A EE03473B1 EE 03473 B1 EE03473 B1 EE 03473B1 EE 9700244 A EE9700244 A EE 9700244A EE 9700244 A EE9700244 A EE 9700244A EE 03473 B1 EE03473 B1 EE 03473B1
Authority
EE
Estonia
Prior art keywords
proton pump
pump inhibitor
pharmaceutical composition
composition
ppi
Prior art date
Application number
EE9700244A
Other languages
English (en)
Estonian (et)
Other versions
EE9700244A (et
Inventor
J. Dave Kaushik
B. Williams James
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9700244A publication Critical patent/EE9700244A/xx
Publication of EE03473B1 publication Critical patent/EE03473B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EE9700244A 1995-04-04 1996-03-29 Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon EE03473B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/416,275 US5708017A (en) 1995-04-04 1995-04-04 Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
PCT/US1996/004355 WO1996031213A1 (fr) 1995-04-04 1996-03-29 Composition pharmaceutique contenant des inhibiteurs de pompe a protons

Publications (2)

Publication Number Publication Date
EE9700244A EE9700244A (et) 1998-04-15
EE03473B1 true EE03473B1 (et) 2001-08-15

Family

ID=23649308

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700244A EE03473B1 (et) 1995-04-04 1996-03-29 Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon

Country Status (30)

Country Link
US (1) US5708017A (fr)
EP (1) EP0819004B1 (fr)
JP (1) JP4603631B2 (fr)
KR (1) KR100419105B1 (fr)
CN (1) CN1080119C (fr)
AT (1) ATE438380T1 (fr)
AU (1) AU703755B2 (fr)
BR (1) BR9604803A (fr)
CA (1) CA2217515C (fr)
CY (1) CY2613B2 (fr)
CZ (1) CZ287297B6 (fr)
DE (1) DE69637985D1 (fr)
DK (1) DK0819004T3 (fr)
EA (1) EA000087B1 (fr)
EE (1) EE03473B1 (fr)
ES (1) ES2329098T3 (fr)
HK (1) HK1004658A1 (fr)
HU (1) HU227864B1 (fr)
IS (1) IS2706B (fr)
MX (1) MX9707694A (fr)
NO (1) NO312994B1 (fr)
NZ (1) NZ305708A (fr)
PL (1) PL183144B1 (fr)
PT (1) PT819004E (fr)
SI (1) SI0819004T1 (fr)
SK (1) SK282872B6 (fr)
TR (1) TR199701117T1 (fr)
UA (1) UA42061C2 (fr)
WO (1) WO1996031213A1 (fr)
ZA (1) ZA962657B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173431B1 (da) * 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
BR9912937A (pt) 1998-08-10 2001-05-08 Partnership Of Michael E Garst Pró-drogas de inibidores de bomba de prótons
AU773696B2 (en) * 1998-10-06 2004-06-03 Mars, Incorporated Animal stereotypy
JP2002537337A (ja) * 1999-02-23 2002-11-05 メルク エンド カムパニー インコーポレーテッド プロトンポンプ阻害薬を含む医薬組成物
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
JP4081273B2 (ja) 1999-10-20 2008-04-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール系化合物安定化方法
GB2358136A (en) * 2000-01-15 2001-07-18 Univ Montfort A medicament for the treatment of equine oral stereotypies using a pH regulator
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
ES2345873T3 (es) * 2000-05-30 2010-10-05 Merial Limited Composiciones para la prevencion de ulceras en caballos.
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
BRPI0114927B8 (pt) * 2000-10-27 2021-05-25 Leo Pharma As composição de gel farmacêutica não aquosa para aplicação na pele, e, uso de uma composição
AU2002231654A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical paste comprising an acid-labile active ingredient
KR20030059318A (ko) * 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
US20050019390A1 (en) * 2001-10-26 2005-01-27 John Kohnke Dosage system and dosage vehicle therefor
AUPS244002A0 (en) * 2002-05-20 2002-06-13 John Kohnke Products Pty Ltd Agent delivery system
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
CA2490142A1 (fr) * 2002-07-03 2004-01-15 Abbott Laboratories Formes dosifiees liquides titrables de medicaments labiles en milieu acide
RU2292342C2 (ru) * 2002-07-19 2007-01-27 Уинстон Фармасьютикалс ЛЛС. Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
JP2006516562A (ja) * 2003-01-24 2006-07-06 ステート オブ イスラエル、ミニストリー オブ アグリカルチャー 抗酸化活性を増強するための相乗的な組成物及び方法
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005000269A1 (fr) * 2003-06-26 2005-01-06 Cipla Limited Preparations pharmaceutiques contenant un inhibiteur de la pompe a protons
WO2005039640A1 (fr) * 2003-10-03 2005-05-06 Allergan Inc. Compositions contenant des peptides en trefle et/ou des mucoadhesifs et des promedicaments d'un inhibiteur de pompe a proton
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
WO2005097083A2 (fr) * 2004-03-30 2005-10-20 Dermatrends,Inc. Administration par voie transdermique d'inhibiteurs de la pompe a protons
CA2561700A1 (fr) * 2004-04-16 2005-12-15 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006026829A1 (fr) * 2004-09-09 2006-03-16 Metelli Pty Ltd Composition en pate stable d'un agent enterique actif labile acide, enrobe, et son utilisation
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2635272C (fr) * 2006-01-27 2016-11-29 Yale University Inhibiteur agissant rapidement de la secretion acide gastrique
CN101453993A (zh) * 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026768B1 (fr) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Formulation pharmaceutique comprenant des unités multiples
WO2008036201A1 (fr) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de pompes à protons comprenant le groupe fonctionnel 1h-imidazo[4,5-b] pyridine
EP2086543A2 (fr) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US20080236409A1 (en) 2007-03-30 2008-10-02 Lyndon Lee Cozzutto Strapping track assembly and methods of using the same
CA2716367C (fr) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprenant une combinaison d'omeprazole et de lansoprazole, et un agent tampon, et ses methodes d'utilisation
EP2262536A4 (fr) * 2008-03-26 2013-07-03 Taro Pharmaceuticals North America Inc Compositions lipidiques stabilisantes pour agents pharmaceutiques oraux
NZ591810A (en) * 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
DE102009018133A1 (de) * 2009-04-15 2010-11-11 Agon Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
GB201306720D0 (en) * 2013-04-12 2013-05-29 Special Products Ltd Formulation
CA2975599A1 (fr) 2015-02-03 2016-08-11 Chiasma Inc. Methode de traitement de maladies
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10137111B2 (en) 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
EP3299017A1 (fr) * 2016-09-23 2018-03-28 The Boots Company PLC Formule
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
EP3720844A4 (fr) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation Compositions de médicaments
GB201804621D0 (en) * 2018-03-22 2018-05-09 Bcm Specials Ltd Formulation
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
GB202116644D0 (en) 2021-11-18 2022-01-05 Innovate Pharmaceuticals Ltd Liquid composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
WO1990000054A1 (fr) * 1988-06-30 1990-01-11 The Upjohn Company Agents anti-secretoires transdermiques pour troubles gastro-intestinaux
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs

Also Published As

Publication number Publication date
SK282872B6 (sk) 2003-01-09
BR9604803A (pt) 1998-06-09
JP4603631B2 (ja) 2010-12-22
SK135097A3 (en) 1998-06-03
EA000087B1 (ru) 1998-06-25
ATE438380T1 (de) 2009-08-15
NO974589L (no) 1997-12-03
CY2613B2 (en) 2011-04-06
UA42061C2 (uk) 2001-10-15
CZ313597A3 (cs) 1998-04-15
EP0819004A4 (fr) 2006-01-18
CA2217515A1 (fr) 1996-10-10
MX9707694A (es) 1997-12-31
EP0819004A1 (fr) 1998-01-21
HK1004658A1 (en) 1998-12-04
ES2329098T3 (es) 2009-11-20
DE69637985D1 (de) 2009-09-17
EE9700244A (et) 1998-04-15
HUP9801626A3 (en) 2000-06-28
EA199700294A1 (ru) 1998-02-26
CZ287297B6 (en) 2000-10-11
CN1080119C (zh) 2002-03-06
AU703755B2 (en) 1999-04-01
SI0819004T1 (sl) 2009-12-31
CN1185107A (zh) 1998-06-17
KR19980703576A (ko) 1998-11-05
DK0819004T3 (da) 2009-11-30
KR100419105B1 (ko) 2004-05-31
US5708017A (en) 1998-01-13
IS2706B (is) 2011-01-15
NO974589D0 (no) 1997-10-03
WO1996031213A1 (fr) 1996-10-10
ZA962657B (en) 1996-10-09
JPH11503160A (ja) 1999-03-23
PT819004E (pt) 2009-10-12
PL183144B1 (pl) 2002-05-31
HU227864B1 (en) 2012-05-29
TR199701117T1 (xx) 1998-02-21
CA2217515C (fr) 2005-03-15
PL322619A1 (en) 1998-02-02
AU5379796A (en) 1996-10-23
HUP9801626A2 (hu) 1999-02-01
IS4576A (is) 1997-10-02
NO312994B1 (no) 2002-07-29
NZ305708A (en) 1999-11-29
EP0819004B1 (fr) 2009-08-05

Similar Documents

Publication Publication Date Title
EE9700244A (et) Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon
BG105754A (en) Pharmaceutical composition containing proton pump inhibitors
DK0696921T3 (da) Veterinært præparat indeholdende en protonpumpeinhibitor
CA2161683A1 (fr) Composition pour medecine veterinaire, renfermant un inhibiteur de la pompe a protons

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name